(Total Views: 547)
Posted On: 05/28/2020 9:13:28 AM
Post# of 149219
https://seekingalpha.com/news/3578165-roche-l...idminus-19
Roche launches new studies of Actemra + remdesivir in COVID-19
May 28, 2020 6:47 AM ET|About: Roche Holding Ltd ADR (RHHBY)
Roche (OTCQX:RHHBY) unit Genentech, in collaboration with Gilead Sciences (NASDAQ:GILD), initiates a Phase 3 clinical trial evaluating the combination of Actemra (tocilizumab) and remdesivir in hospitalized patients with severe COVID-19 pneumonia.
The randomized 450-subject study, REMDACTA, will compare the combo to placebo + remdesivir.
Enrollment in another Phase 3, COVACTA, evaluating Actemra + standard-of-care (SOC) treatment in these patients is close to completion. Top line data should be available this summer.
A third Phase 3, EMPACTA, evaluating Actemra compared to SOC in ~375 of these patients in underserved areas has been initiated.
Roche launches new studies of Actemra + remdesivir in COVID-19
May 28, 2020 6:47 AM ET|About: Roche Holding Ltd ADR (RHHBY)
Roche (OTCQX:RHHBY) unit Genentech, in collaboration with Gilead Sciences (NASDAQ:GILD), initiates a Phase 3 clinical trial evaluating the combination of Actemra (tocilizumab) and remdesivir in hospitalized patients with severe COVID-19 pneumonia.
The randomized 450-subject study, REMDACTA, will compare the combo to placebo + remdesivir.
Enrollment in another Phase 3, COVACTA, evaluating Actemra + standard-of-care (SOC) treatment in these patients is close to completion. Top line data should be available this summer.
A third Phase 3, EMPACTA, evaluating Actemra compared to SOC in ~375 of these patients in underserved areas has been initiated.
(0)
(0)Scroll down for more posts ▼
